New psoriasis therapies have increased the ability for patients to achieve skin clearance. However, more evidence is needed on the impact of total skin clearance from the patient perspective.
Researchers set out to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. For the study, which was published online ahead of print in The Journal of the American Academy of Dermatology, Strober et al analyzed pooled data from 3 phase-III trials to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI).
Results showed that percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P< .001). Respective percentages with DLQI score 0/1 were 80% and 55% (P< .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for DLQI score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1.
The researchers concluded that complete skin clearance is a clinically meaningful end point and outcome for patients. This is reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life, they said.
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. Published online ahead of print May 17, 2016. doi: 10.1016/j.jaad.2016.03.026.
New psoriasis therapies have increased the ability for patients to achieve skin clearance. However, more evidence is needed on the impact of total skin clearance from the patient perspective.
Researchers set out to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. For the study, which was published online ahead of print in The Journal of the American Academy of Dermatology, Strober et al analyzed pooled data from 3 phase-III trials to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI).
Results showed that percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P< .001). Respective percentages with DLQI score 0/1 were 80% and 55% (P< .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for DLQI score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1.
The researchers concluded that complete skin clearance is a clinically meaningful end point and outcome for patients. This is reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life, they said.
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. Published online ahead of print May 17, 2016. doi: 10.1016/j.jaad.2016.03.026.
New psoriasis therapies have increased the ability for patients to achieve skin clearance. However, more evidence is needed on the impact of total skin clearance from the patient perspective.
Researchers set out to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. For the study, which was published online ahead of print in The Journal of the American Academy of Dermatology, Strober et al analyzed pooled data from 3 phase-III trials to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI).
Results showed that percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P< .001). Respective percentages with DLQI score 0/1 were 80% and 55% (P< .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for DLQI score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1.
The researchers concluded that complete skin clearance is a clinically meaningful end point and outcome for patients. This is reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life, they said.
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. Published online ahead of print May 17, 2016. doi: 10.1016/j.jaad.2016.03.026.
